Suppression by progabide of ethanol withdrawal syndrome in rats.
Progabide, a specific and clinically used GABA receptor agonist, was tested for its ability to suppress ethanol withdrawal syndrome. Male rats were rendered physically dependent on ethanol by feeding for 12 days on a liquid diet in which ethanol isocalorically replaced dextrose. Progabide (100-400 mg/kg i.p.), administered 8 h after ethanol was withdrawn, produced a dose-related inhibition of both tremors and audiogenically induced seizures. A single dose of 400 mg/kg of progabide completely suppressed all ethanol withdrawal reactions. Seizures were more sensitive to the drug than tremors. The results support the view that a decrease in GABA transmission plays a role in ethanol withdrawal symptoms and suggest that progabide may be tested as a possible treatment of ethanol withdrawal syndrome in man.
Fadda
F
F
Mosca
E
E
Meloni
R
R
Gessa
G L
GL
D000161:Acoustic Stimulation; D000818:Animals; D000431:Ethanol / Q000009:adverse effects*; D006801:Humans; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012640:Seizures / Q000188:drug therapy; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D009435:Synaptic Transmission; D014202:Tremor / Q000188:drug therapy; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000502:physiology / Q000627:therapeutic use
C017985:progabide; D000431:Ethanol; D005680:gamma-Aminobutyric Acid